HACK

HACK.AX was created on 2016-08-30 by BetaShares. The fund's investment portfolio concentrates primarily on theme equity. The fund aims to track the performance of an index (before fees and expenses) that provides exposure to the leading companies in the global cybersecurity sector.

Adalta Limited

1AD

AdAlta Ltd. operates as a biotechnology company, discovers, develops, and commercializes protein based therapeutics. The company is headquartered in Melbourne, Victoria. The company went IPO on 2016-08-22. The firm is engaged in the development of therapeutic products from its i-body platform. The firm has five active development programs ranging from discovery to Phase II clinical trials with applications in the fields of inflammation/fibrosis and immuno-oncology. Its lead product, AD-214, is an antibody therapeutic for the treatment of fibrotic diseases, including lung fibrosis (specifically Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD)), kidney fibrosis, eye fibrosis and some cancers. Chimeric Antigen Receptor (CAR) cell therapies involve modification of a patient’s immune cells (T cells, NK cells, macrophages and other) so that they produce a CAR on the cell surface that enables the patient’s immune system to recognize and kill diseased cells such as cancer. The company develops i-body enabled PET (i-PET) imaging agents for use in immuno-oncology. The company evaluates several CXCR4 i-bodies.

Grange Resources Limited

GRR

Grange Resources Ltd. engages in the mining, processing, exploration, evaluation, and development of mineral resources and iron ore. The company is headquartered in Burnie, Tasmania. The principal activities of the Company consist of the mining, processing and sale of iron ore; and the ongoing exploration, evaluation and development of mineral resources. Its projects include Savage River, Port Latta and Southdown. The Savage River project is a magnetite iron ore mine, which is located approximately 100 kilometers (km) southwest of the city of Burnie. The Port Latta project is located approximately 70 km northwest of Burnie is Grange Resources' 100%-owned pellet plant and port facility at Port Latta, which produces approximately 2.2 million tons of premium quality iron ore products annually. The Southdown project is located approximately 90 km from Albany in Western Australia's Great Southern region, Southdown is a joint venture between Grange (70%) and SRT Australia Pty Ltd (30%).

Hazer Group Limited

HZR

Hazer Group Ltd. engages in the research and development of novel graphite, and hydrogen production technology. The company is headquartered in Perth, Western Australia. The company went IPO on 2015-12-02. The Company’s process enables the conversion of natural gas and similar feedstocks, into hydrogen and graphite, using iron ore as a process catalyst. Its Hazer Process focuses on savings for the hydrogen producer, as well as providing clean hydrogen with lower carbon dioxide emissions, enabling such hydrogen to be used in a range of developing clean energy applications, as well as in existing chemical processing industries. The HAZER Process produces synthetic graphite. The firm's markets include industrial hydrogen, hydrogen mobility and synthetic graphite. The company also has facilities, including a research and development lab and a fluid bed reactor pilot plant.

Kazia Therapeutics Limited

KZA

Kazia Therapeutics Ltd. is a clinical stage oncology company It engages in the pharmaceutical research and development business. The company is headquartered in Sydney, New South Wales. The firm is engaged in pharmaceutical research and development. The Company’s drug candidates are designed to treat diseases such as brain cancer, renal cancer, and liver cancer. The Company’s lead programs include paxalisib and EVT801. Paxalisib is a small molecule, brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, a central regulator of growth and cell division that is dysregulated in many types of cancer. Paxalisib is being developed for several forms of brain cancer. EVT801 is a small molecule inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3). EVT801 is being developed in patients with advanced cancer. EVT801 targets angiogenesis, the formation of new blood vessels around a tumor.